Innovations CfP Focus Area 2: Vaccine candidates for priority pathogens and viral families

The objective for Focus Area 2 is to advance new vaccine candidates for CEPI priority pathogens and viral families, aligned with CEPI’s strategic objectives to accelerate development of vaccines against known high-risk pathogens and to build a library of exemplar vaccines against prototype viruses from high-risk viral families to give a head-start on novel threats (Disease X).

CEPI offers support for vaccine candidate research and development through the following award mechanisms:

Exploratory Award: Up to US $1M over a maximum of 18 months to support the design and early stage testing of new vaccine candidates.

Preclinical Development Award: Up to US $5M to demonstrate preclinical proof of concept. In-scope activities include preclinical efficacy studies, studies that support regulatory filing (e.g., IND enabling studies), and CMC development related to analytical methods, process optimization, characterization, and scale-up, and/or formulation.

Clinical Development Award: Up to five years of support for clinical testing of a vaccine candidate. In-scope activities include conduct of Phase I through Phase III studies

PRIORITY PATHOGENS Lassa Fever

Research Authority due date: 6.7.26